Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| 3-D Matrix Europe SAS | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
PuraStat is a viscous solution of synthetic peptides that provides a physical barrier to facilitate hemostasis. It is indicated for haemostasis in a variety of surgical indications. In this study the efficacy of PuraStat in reducing delayed bleeding following duodenal endoscopic mucosal resection (EMR) will be assessed. PuraStat will be applied to the EMR defect after the resection. The presence of active bleeding or high risk stigma of bleeding will be observed on an esophagogastroduodenoscopy (EGD) performed 1 day after the duodenal EMR. Furthermore the presence of clinical signs of delayed bleeding, other adverse events and the feasibility of PuraStat application will be assessed.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Duodenal EMR + PuraStat | Other | PuraStat will be applied to the defect after duodenal EMR of the lesion |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PuraStat | Device | Purastat is applied to the EMR defect |
|
| Measure | Description | Time Frame |
|---|---|---|
| The presence of active bleeding or high risk stigma of bleeding | On an EGD, performed the day after the duodenal EMR with PuraStat application, the presence of active bleeding or the presence of visible vessels after removal of a blood clot will be observed | 1 day after EMR |
| Measure | Description | Time Frame |
|---|---|---|
| The presence of clinical signs of delayed bleeding | The presence of hematemesis, melena, hemoglobin/hematocrit drop, hypotension or shock will be observed in the patients that had duodenal EMR with PuraStat application. | 'During hospital stay, assessed up to 10 days' and '30 days after EMR' |
| The presence of other adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Raf Bisschops | Contact | +3216342161 | raf.bisschops@uzleuven.be | |
| Ingrid Demedts | Contact | +3216345518 | ingrid.demedts@uzleuven.be |
| Name | Affiliation | Role |
|---|---|---|
| Ingrid Demedts | UZ Leuven | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospitals Leuven | Recruiting | Leuven | 3000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The presence of adverse events like perforation, severe pain, fever… will be observed in the patients that had duodenal EMR with Purastat application |
| 'During hospital stay, assessed up to 10 days' and '30 days after EMR' |
| The feasibility of PuraStat application: Amount | The amount of PuraStat will be investigated: Volume in mL | During EMR procedure |
| The feasibility of PuraStat application: Ease | The ease of application will be investigated: Questionnaire will be answered by the endoscopist. | During EMR procedure |
| The feasibility of Purastat application: Coverage | Is PuraStat covering the resection defect the day after the EMR? This will be investigated by questionnaire that will be answered by the endoscopist who performs the EGD | During EGD procedure |